| Today’s Big NewsSep 7, 2023 |
| By James Waldron Roche’s $310 million splash into the metabolic therapy pool two months ago already appears to be paying off, with its Alnylam-partnered hypertension med reducing blood pressure in a phase 2 trial. |
|
|
|
By Nick Paul Taylor Pfizer and Valneva have ticked off another milestone in their Lyme disease vaccine program, showing that booster doses safely trigger immune responses in adolescents and younger children in a phase 2 clinical trial. |
By James Waldron What do you get when you combine the established cancer modality of antibody-drug conjugation with targeted protein degradation? An intriguing new class of antibody drugs called degrader-antibody conjugates—and Seagen is keen to get in on the ground floor. |
By Nick Paul Taylor Vaxart is still looking a little queasy. The biotech delivered mixed data on its oral monovalent norovirus vaccine candidate, with the failure to cut acute gastroenteritis in the challenge study ensuring a muted response from investors despite successes on other endpoints. |
|
October 16-18, 2023 | Boston, MA Hear from leading experts as they share their experiences and insights covering drug development from the earliest stage of research to FDA approval. Register today & Save $200!
|
|
By Gabrielle Masson Investors have reached deep into their pocketbooks for Mariana Oncology’s series B financing, with Eli Lilly coming aboard for the oversubscribed $175 million round aimed at making waves in radiopharmaceutical development. |
By Annalee Armstrong CymaBay has always believed in its liver disease med seladelpar, even after a 2019 failure in nonalcoholic steatohepatitis (NASH). Now, the drug has shown its mettle in a phase 3 study of patients with primary biliary cholangitis, teeing up regulatory discussions. |
By Helen Floersh Novo Nordisk will collaborate with Harvard and the Broad Institute of Massachusetts Institute of Technology to develop three new programs over the next three years to tackle diabetes and cardiac fibrosis. |
By Nick Paul Taylor PhRMA has rounded up its attack ad team once again for another broadside against pharmacy benefit managers, zeroing in this time on the potential for insurers to profit from where prescriptions get filled. |
By Kevin Dunleavy Now that the CMS has revealed its list of the first 10 drugs subject to Medicare price negotiations under the Inflation Reduction Act, it’s time to consider the financial implications for affected companies. |
By Joseph Keenan Trialbee, which specializes in patient recruitment, launched a new tool to help alleviate patient recruitment delays for clinical trials. |
By Dave Muoio The two new initiatives leverage cultural representation and targeted messaging to reach audiences impacted by health inequity, Google's Garth Graham, M.D., said. |
By Joseph Keenan The London-based private equity firm Permira shelled out 703.1 million pounds sterling ($886.40 million) to take the CRO Ergomed Clinical Research private. |
By Joseph Keenan Singapore-based Harvest Integrated Research Organization, or HiRO, has expanded its global footprint with the acquisition of Courante Oncology, a Minnesota-based CRO that specializes in oncology. |
By Ayla Ellison Patient advocates are addressing the web of challenges and inequalities that exist within the healthcare landscape. Patient advocacy is a cornerstone of positive change, and it is one of the five categories that will shape the Fierce 50. |
|
Wednesday, September 13, 2023 | 12pm ET / 9am PT Developing a cell therapy product is incredibly complex. Speed to clinic and market are imperative to reduce overall costs and maintain competitive market advantages. Join us to learn how to leverage an established lentiviral vector (LVV) process for accelerating drug product development. Register today.
|
|
| Whitepaper Access this insightful whitepaper to explore the role collaboration platform technology can play in helping address current industry challenges and to generate business value. Sponsored by: Zoom |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| Whitepaper15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
